Background Keverprazan is a novel potassium-competitive acid blocker for the treatment of
acid-related diseases. Aims To evaluate the safety, pharmacokinetics, pharmacodynamics …

Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …

Summary Background Zastaprazan (JP‐1366) is a novel potassium‐competitive acid
blocker with favourable preclinical safety and efficacy profile being developed for the …

Abstract Keverprazan hydrochloride (凯普拉生) is a potassium ion competitive acid blocker
that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid …

Summary Background Tegoprazan (CJ‐12420) is a potassium‐competitive acid blocker (P‐
CAB) with therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly …

Proton pump inhibitors (PPIs) are widely prescribed as first-line therapy for the treatment of
acid-related diseases, such as peptic ulcers and gastro-esophageal reflux disease, and for …

Vonoprazan fumarate (Takecab®) is a first-in-class potassium-competitive acid blocker that
has been available in the market in Japan since February 2015. Vonoprazan is …

Abstract Background and Aim Considering the limitation of varying acid suppression of
proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect …

Summary Background TAK‐438 (vonoprazan) is a potassium‐competitive acid blocker that
reversibly inhibits gastric H+, K+‐ATP ase. Aim To evaluate the safety, tolerability …

Background Potassium‐competitive acid blockers (P‐CABs) are emerging as novel
treatments for acid‐related disorders including gastroesophageal reflux disease …